OXIS INTERNATIONAL Inactive Instrument
Oxis International Stock OTC Bulletin Board
Equities
US6918295014
Pharmaceuticals
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 4.31M 5.86M |
|---|---|---|---|---|---|
| Net income 2024 * | -17M -23.14M | Net income 2025 * | - | EV / Sales 2024 * | - |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-0.29
x | P/E ratio 2025 * |
-
| Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 81.75% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| Managers | Title | Age | Since |
|---|---|---|---|
Michael Breen
CEO | Chief Executive Officer | 62 | 21-01-12 |
Manu Ohri
DFI | Director of Finance/CFO | 67 | 22-02-17 |
Jeffrey Miller
PRN | Corporate Officer/Principal | - | 22-12-13 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 78 | 23-04-30 | |
Bruce Wendel
BRD | Director/Board Member | 70 | 20-11-10 |
Rajesh Shrotriya
BRD | Director/Board Member | 79 | 21-01-12 |
GT Biopharma, Inc. specializes in the research and development of therapeutic products used primarily for the treatment of cancer and disorders of the central nervous system.
The group has a portfolio of 3 products in clinical development phase (GTB-3550, GTB-3650 and GTB-5550; treatment of leukemia and solid tumors).
Sector
Pharmaceuticals
Calendar
2024-06-25
- Annual General Meeting
| 1st Jan change | Capi. | |
|---|---|---|
| +32.09% | 693B | |
| +29.39% | 584B | |
| -1.34% | 372B | |
| +20.34% | 332B | |
| +7.39% | 294B | |
| +14.25% | 239B | |
| -3.03% | 211B | |
| +10.02% | 210B | |
| +8.49% | 168B |
